Zacks Investment Research upgraded shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a hold rating to a strong-buy rating in a research report released on Friday. The firm currently has $3.00 price objective on the biopharmaceutical company’s stock.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Other equities analysts have also issued reports about the stock. ValuEngine lowered shares of AEterna Zentaris from a hold rating to a sell rating in a report on Friday, August 10th. HC Wainwright restated a buy rating and issued a $3.00 price objective on shares of AEterna Zentaris in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $3.33.

Shares of NASDAQ AEZS opened at $3.00 on Friday. AEterna Zentaris has a fifty-two week low of $1.12 and a fifty-two week high of $3.25. The company has a market capitalization of $47.68 million, a P/E ratio of -2.22 and a beta of 0.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. AEterna Zentaris had a net margin of 34.40% and a return on equity of 83.33%. The business had revenue of $0.66 million for the quarter. Equities analysts predict that AEterna Zentaris will post 0.44 EPS for the current fiscal year.

A hedge fund recently bought a new stake in AEterna Zentaris stock. Virtu Financial LLC bought a new stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 51,028 shares of the biopharmaceutical company’s stock, valued at approximately $101,000. Virtu Financial LLC owned approximately 0.31% of AEterna Zentaris as of its most recent filing with the Securities and Exchange Commission (SEC). 3.51% of the stock is currently owned by institutional investors.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

See Also: Using the New Google Finance Tool

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.